La Jolla-based Fate Therapeutics, a firm developing stem cell technology, said today that it has named Ken Batchelor, Ph.D., as the firm's Chief Scientific Officer. Batchelor joins the firm GlaxoSmithKline, where he was most recently Senior Vice President. According to the company, Batchelor has more than 28 years of experience in drug discovery and development. Fate Therapeutics' founders are from Harvard, Stanford, The Scripps Research Institute, the University of Washington and the Whitehead Institute for Biomedical Research.
Top NewsThursday, March 12, 2009
Fate Therapeutics Names Chief Scientific Officer